Serotonin receptor and transporter ligands - Current status

被引:71
作者
Oh, SJ
Ha, HJ [1 ]
Chi, DY
Lee, HK
机构
[1] Hankuk Univ Foreign Studies, Dept Chem, Yongin 449791, Kyunggi Do, South Korea
[2] Inha Univ, Dept Chem, Inchon 402751, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Nucl Med, Seoul 138736, South Korea
关键词
D O I
10.2174/0929867013372599
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The serotonin (5-HT) receptor system has 14 different subtypes classified by pharmacology and function. Many ligands are widely used for therapeutic and diagnostic purposes in some severe human diseases. Most of the ligands that are specific for each 5-HT receptor have distinctive chemical structures with regard to pharmacophore elements including 4-arylpiperazine, benzimidazole, benzamide, chroman, aminopyridazine, tetralin, and polycycles. However, their affinity and selectivity for 5-HT, dopamine and alpha1 receptors depend on their substituents and linker spacers. 5-HT transporter inhibitors have also been developed as potential antidepressants. In contrast to classical tricyclic compounds, newly developed secondary amine derivatives such as paroxetine and tetralin show high binding affinity and selectivity. Radioisotope-labeled ligands have also been developed, including [carbonyl-C-11]WAY 100635 for 5-HT1A receptor, [C-11 or F-18]ketanserine derivatives for 5-HT2 receptor, [I-125]DAIZAC for 5-HT3 receptor, and [I-123]IDAM for 5-HT transporter, and these are accumulated in brain regions that are rich in the respective receptors. This review summarizes the recent development of 5-HT receptor- and transporter-specific ligands and their pharmacological properties on the basis of their chemical structures.
引用
收藏
页码:999 / 1034
页数:36
相关论文
共 181 条
[1]  
AARON PM, 1996, J MED CHEM, V39, P2953
[2]  
ADHAM N, 1992, MOL PHARMACOL, V41, P1
[3]   A novel organometallic aqua complex of technetium for the labeling of biomolecules:: Synthesis of [99mTc(OH2)3(CO)3]+ from [99mTcO4]- in aqueous solution and its reaction with a bifunctional ligand [J].
Alberto, R ;
Schibli, R ;
Egli, A ;
Schubiger, AP ;
Abram, U ;
Kaden, TA .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1998, 120 (31) :7987-7988
[4]   First application of fac-[99mTc(OH2)3(CO)3]+ in bioorganometallic chemistry:: Design, structure, and in vitro affinity of a 5-HT1A receptor ligand labeled with 99mTc [J].
Alberto, R ;
Schibli, R ;
Schubiger, AP ;
Abram, U ;
Pietzsch, HJ ;
Johannsen, B .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1999, 121 (25) :6076-6077
[5]   Radiosynthesis of [11C]Lu 29-024:: A potential radiotracer for 5HT2 receptors PET studies [J].
Amokhtari, M ;
Andersen, K ;
Ibazizene, M ;
Dhilly, M ;
Dauphin, F ;
Barre, L .
NUCLEAR MEDICINE AND BIOLOGY, 1998, 25 (06) :517-522
[6]   Potent, selective tetrahydro-beta-carboline antagonists of the serotonin 2B (5HT(2B)) contractile receptor in the rat stomach fundus [J].
Audia, JE ;
Evrard, DA ;
Murdoch, GR ;
Droste, JJ ;
Nissen, JS ;
Schenck, KW ;
Fludzinski, P ;
Lucaites, VL ;
Nelson, DL ;
Cohen, ML .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (14) :2773-2780
[7]   123I-5-I-R91150, a new single-photon emission tomography ligand for 5-HT2A receptors:: influence of age and gender in healthy subjects [J].
Baeken, C ;
D'haenen, H ;
Flamen, P ;
Mertens, J ;
Terriere, D ;
Chavatte, K ;
Boumon, R ;
Bossuyt, A .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1998, 25 (12) :1617-1622
[8]   5-HT1D receptor agonist properties of novel 2-[5-[[(trifluoromethyl)sulfonyl]oxy]indolyl]ethylamines and their use as synthetic intermediates [J].
Barf, TA ;
deBoer, P ;
Wikstrom, H ;
Peroutka, SJ ;
Svensson, K ;
Ennis, MD ;
Ghazal, NB ;
McGuire, JC ;
Smith, MW .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (24) :4717-4726
[9]   BEHAVIORAL PHARMACOLOGY OF 5-HT3-RECEPTOR LIGANDS [J].
BARNES, JM ;
BARNES, NM ;
COOPER, SJ .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 1992, 16 (01) :107-113
[10]   A review of central 5-HT receptors and their function [J].
Barnes, NM ;
Sharp, T .
NEUROPHARMACOLOGY, 1999, 38 (08) :1083-1152